Bosh sahifaAMRN • NASDAQ
add
Amarin Corporation PLC
Yopilish kursi
9,36 $
Kunlik diapazon
8,84 $ - 9,34 $
Yillik diapazon
7,08 $ - 20,60 $
Bozor kapitalizatsiyasi
182,40 mln USD
Oʻrtacha hajm
123,10 ming
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 62,31 mln | -16,61% |
Joriy xarajat | 42,96 mln | -13,63% |
Sof foyda | -48,62 mln | -741,00% |
Sof foyda marjasi | -78,03 | -908,14% |
Har bir ulushga tushum | -0,40 | — |
EBITDA | -15,31 mln | -295,22% |
Amaldagi soliq stavkasi | 2,58% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 294,22 mln | -8,25% |
Jami aktivlari | 685,35 mln | -17,60% |
Jami passivlari | 199,17 mln | -28,76% |
Umumiy kapital | 486,18 mln | — |
Tarqatilgan aksiyalar | 20,71 mln | — |
Narxi/balansdagi bahosi | 0,40 | — |
Aktivlardan daromad | -5,59% | — |
Kapitaldan daromad | -7,75% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -48,62 mln | -741,00% |
Operatsiyalardan naqd pul | -13,31 mln | -1 963,57% |
Sarmoyadan naqd pul | -22,84 mln | 67,83% |
Moliyadan naqd pul | 17,00 ming | -79,52% |
Naqd pulning sof oʻzgarishi | -36,13 mln | 49,51% |
Boʻsh pul | 13,85 mln | 215,08% |
Haqida
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Tashkil etilgan
1-mar, 1989
Bosh ofis
Sayt
Xodimlar soni
275
